GAITHERSBURG, Md., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced progress in its collaboration with Takeda Pharmaceutical Company Limited, originally announced in August. The companies have signed an exclusive license agreement for Takeda’s development, manufacturing and commercialization of NVX-CoV2373, Novavax’ COVID-19 vaccine candidate, in Japan. Additionally, Takeda dosed the first participants in a Phase 2 clinical trial to test the immunogenicity and safety of Novavax’ vaccine candidate in the Japanese population.
Related Post
- Tauriga Sciences Inc. Showcases Blister Pack Design for its Evergreen Mint Flavor, Delta 8 THC Infused, Version of Tauri-Gum - April 18th, 2021
- Immutep Receives A$1,155,055 R&D Tax Incentive - April 18th, 2021
- New Data at AAN 2021 from Across Biogen’s MS Portfolio Demonstrate Positive Impact of Treatment on People Living with Relapsing Multiple Sclerosis - April 18th, 2021
- TG Therapeutics Announces Positive Results from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at... - April 18th, 2021
- Zogenix Presents New Data from a Study Highlighting the Impact of Treatment with FINTEPLA® (Fenfluramine) Oral Solution on Dravet Syndrome Patients,... - April 18th, 2021
- Fulgent Genetics to Announce First Quarter 2021 Financial Results on Thursday May 6, 2021 - April 18th, 2021
- Aleafia Health to Announce 2021 First Quarter Results - April 18th, 2021
- Aprea Therapeutics to Host Virtual R&D Day on April 22, 2021 - April 18th, 2021
- Vistin Pharma ASA: Invitation to Q1 2021 conference call - April 18th, 2021
- LIDDS Annual Report 2020 - April 18th, 2021
- Adverum Biotechnologies to Present New Data from the OPTIC Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at ARVO 2021 - April 18th, 2021
- Virbac : Declaration of the number of shares and voting rights March 2021 - April 18th, 2021
- Sanofi completes Kiadis acquisition - April 18th, 2021
- Brickell Biotech Announces Presentation of US Phase 3 Open-Label Long-Term Safety Study Results for Sofpironium Bromide Gel at the Late-Breaking... - April 18th, 2021
- Cosmos Holdings Reports Revenue Growth of 40% to a Record $55.4 Million and Achieves Profitability for 2020 - April 18th, 2021
- Auxly Receives Approval to Begin Trading on the Toronto Stock Exchange April 20, 2021 - April 18th, 2021
- AnPac Bio Reports Record Q1 for Paid CDA-Based Cancer Testing Volume in 2021, Increasing Approximately 130% Compared to Q1, 2020 - April 18th, 2021
- Apellis to Showcase Leadership in Retina at Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting - April 18th, 2021
- Avadel Presents New Data from its Pivotal REST-ON Phase 3 Trial of FT218, once-nightly sodium oxybate, at the 2021 American Academy of Neurology... - April 18th, 2021
- VASCEPA® (Icosapent Ethyl) Reported to Impact Vulnerable Coronary Plaque Features in New Analyses of EVAPORATE Study Presented as Late-Breaking... - April 18th, 2021
- Virbac: very strong growth in revenue in the first quarter of 2021 at +22.6% at comparable exchange rates and scope (+12.3% at constant rates), driven... - April 16th, 2021
- GBS, Inc. Receives Approval to Commence Validation Clinical Study for Rapid SARS-CoV-2 Diagnostic Test - April 16th, 2021
- TG Therapeutics to Host Investor & Analyst Event to Preview Results from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple... - April 16th, 2021
- Infant Bacterial Therapeutics receives additional patent protection in China - April 16th, 2021
- Nabriva Commences Exclusive Distribution of SIVEXTRO® (tedizolid phosphate) in the U.S. - April 16th, 2021
- GigaGen Publishes Research on Company’s Recombinant Hyperimmunes in Nature Biotechnology - April 16th, 2021
- Pacific Biosciences of California, Inc. First Quarter 2021 Financial Results Call - April 16th, 2021
- Avid Bioservices Announces Completion of Redemption of Series E Convertible Preferred Stock - April 16th, 2021
- Collegium to Host Conference Call to Discuss First Quarter 2021 Financial Results and Provide Corporate Update - April 16th, 2021
- Adamis Pharmaceuticals Announces 2020 Financial Results and Business Update - April 16th, 2021
- Biogen Grows Presence in China with the Approval of TECFIDERA® (dimethyl fumarate) for the Treatment of Relapsing Multiple Sclerosis - April 16th, 2021
- Praxis Precision Medicines Adds Development Expertise to Board of Directors with Appointment of Jeffrey Chodakewitz, M.D. - April 16th, 2021
- 22nd Century Stands Fully Prepared to Enable New Zealand Proposal to Advance Nationwide Smoke-Free Action Plan - April 16th, 2021
- Golden Leaf to Report Fiscal 2020 and Fourth Quarter 2020 Results on Tuesday April 27th - April 16th, 2021
- Tower One Construction Update for the Month of March 2021 - April 16th, 2021
- ContraFect Invited to Present at the Inaugural Anti-Infectives Drug Development Summit - April 16th, 2021
- Revive Reschedules Annual and Special Meeting and Provides Dial-In Information - April 16th, 2021
- Relay Therapeutics Extends Leadership in Integrating Computational and Experimental Approaches to Create Precision Medicines by Acquiring ZebiAI - April 16th, 2021
- Prostate cancer study to be initiated at Uppsala University Hospital with NanoZolid technology® - April 16th, 2021
- New data for Roche’s OCREVUS (ocrelizumab) reinforce significant benefit on slowing disease progression in relapsing and primary progressive... - April 16th, 2021
- AzurRx BioPharma Engages PPD to Manage Clinical Trial for Niclosamide as Treatment for Grade 1 Immune Checkpoint Inhibitor-Associated Colitis - April 14th, 2021
- Artelo Biosciences Reports Second Quarter Fiscal 2021 Financial Results and Provides Business Update - April 14th, 2021
- Longeveron Announces Positive Results of Phase I Clinical Study of Lomecel-B Cell Therapy for Alzheimer’s Disease - April 14th, 2021
- SEngine Precision Medicine Presents Data at 2021 AACR Annual Meeting Demonstrating Clinical Utility and Predictive Value of PARIS® Test in Ovarian... - April 14th, 2021
- Akouos Receives Orphan Drug and Rare Pediatric Disease Designations for AK-OTOF for the Treatment of Otoferlin Gene-Mediated Hearing Loss - April 14th, 2021
- Senti Bio Enters Collaboration with Spark Therapeutics to Develop Next-Generation Precision Gene Therapies - April 14th, 2021
- Passing of Genmab A/S’ Annual General Meeting - April 14th, 2021
- A civil case has been initiated in the claim of JSC Olainfarm for the damage caused - April 14th, 2021
- GeneThera’s Strategy for the Development of a Global Zoonotic Diseases Surveillance System Using Smart Testing Technology - April 14th, 2021
- Nicox: 2021 Ordinary and Extraordinary General Meetings postponed to April 28, 2021 - April 14th, 2021
- Lixte Biotechnology Holdings, Inc. Announces the Appointment of Gil N Schwartzberg to its Board of Directors - April 14th, 2021
- NKMax and Merck KGaA, Darmstadt, Germany Expand Clinical Collaboration to Include Phase I/IIa Trial Investigating the Combination of SNK01 with... - April 14th, 2021
- Tauriga Sciences Inc. to Launch Non-Fungible Tokens (NFTs) Creation & Content Division, as Part of its Long-Term Branding, Marketing, and... - April 14th, 2021
- Notice of Annual General Meeting of LIDDS AB (publ) - April 14th, 2021
- Adamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2020 Financial Results Conference Call and Business Update - April 14th, 2021
- PRA Health Sciences selected by Maryland State Medical Society to supply remote patient monitoring and telehealth services - April 14th, 2021
- Nurix Therapeutics Reports First Quarter Fiscal 2021 Financial Results and Provides a Corporate Update - April 14th, 2021
- BIOPHYTIS Identifies False Report Regarding COVA study - April 14th, 2021
- Constitution of the Board of Directors in Genmab A/S and Grant of Restricted Stock Units and Warrants to Employees and a New Member of Management in... - April 14th, 2021
- ProQR Announces Publication in Nature Medicine for Sepofarsen in Leber Congenital Amaurosis 10 - April 14th, 2021
- Black Diamond Therapeutics Announces Preclinical Data Presentations on BDTX-189 and BDTX-1535 at American Association for Cancer Research Annual... - April 10th, 2021
- Gennao Bio Presents New Data on Novel Gene Monoclonal Antibody Platform Technology at the American Association for Cancer Research (AACR) 2021 Annual... - April 10th, 2021
- MacroGenics Announces Presentations at the 2021 AACR Annual Meeting - April 10th, 2021
- Kronos Bio Presents Preclinical Data for Oral CDK9 Inhibitor KB-0742 Demonstrating Sustained Inhibition of Tumor Growth in Multiple Cancers at AACR... - April 10th, 2021
- Allogene Therapeutics Presents Preclinical Research Highlighting a Novel TurboCAR™ T Cell Technology Designed to Overcome Immune Suppression in... - April 10th, 2021
- NextCure Presents Preclinical Data for NC762 at American Association for Cancer Research (AACR) Annual Meeting 2021 - April 10th, 2021
- Achilles Therapeutics Demonstrates cNeT Product Characterization and Post-Infusion Tracking in a Patient Case Study at the American Association for... - April 10th, 2021
- Harpoon Therapeutics Announces Data from Poster Presentations at the AACR Annual Meeting 2021 - April 10th, 2021
- iTeos Therapeutics Announces New Preliminary Data Indicating Clinical Activity with its Anti-TIGIT Antibody, EOS-448, at the AACR Annual Meeting 2021 - April 10th, 2021
- CRISPR Therapeutics Presents Preclinical Data at AACR 2021 Supporting CD70 Knockout as a Novel Approach to Increasing CAR-T Cell Function - April 10th, 2021
- Inivata Presents New Data in Support of its Liquid Biopsy Technologies at AACR Virtual Annual Meeting 2021 - April 10th, 2021
- Codiak Presents Data at AACR 2021 Demonstrating Potential of Engineered Exosomes to Enhance the Therapeutic Index of Well-Validated Cancer... - April 10th, 2021
- Genocea to Present Novel Preclinical Inhibigen™ Data at AACR Annual Meeting 2021 - April 10th, 2021
- OncXerna Therapeutics Provides New Results from its Xerna™ RNA-based Biomarker Platform at the AACR Annual Meeting - April 10th, 2021
- HOOKIPA announces positive preliminary Phase 1 immunogenicity data for its immunotherapy candidates to treat advanced HPV16+ cancers - April 10th, 2021
- Vincerx Pharma Presents Preclinical Data on VIP236, its Lead Small Molecule Drug Conjugate, at the American Association for Cancer Research Annual... - April 10th, 2021
- Jounce Therapeutics Presents Preclinical Data from JTX-8064/LILRB2 Program at the 2021 American Association for Cancer Research (AACR) Virtual Annual... - April 10th, 2021
- Advaxis Presents Translational Biomarker Data from Ongoing ADXS-503 Phase 1/2 Lung Cancer Trial at the American Associated for Cancer Research (AACR)... - April 10th, 2021
- TCR² Highlights Gavo-cel Translational Data and Emerging Solid Tumor Pipeline Preclinical Data at AACR Annual Meeting - April 10th, 2021
- Arch Oncology Presents New Preclinical T-ALL Data on Highly-differentiated Anti-CD47 Antibody AO-176 at AACR 2021 - April 10th, 2021
Recent Comments